Interferon Could Help CML Patients Stop TKI Therapy

News | April 07, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma By Cancer Network Staff Interferon alpha 2a molecule.

Results from a small study suggest that induction treatment with interferon alpha 2a (IFN) along with imatinib, followed by temporary IFN maintenance therapy, could help patients with chronic myeloid leukemia (CML) discontinue imatinib treatment.